csirt@kutim:~/threat-intel/cve/CVE-2026-22729

Katalog CVE

CVSS 8.6 · High EPSS 0,53%

Kerentanan Improper Neutralization of Special Elements used in an Expression Language Statement ('Expression Language Injection') pada vmware spring ai. Skor CVSS 3.1 8.6 (High) menurut vmware.com.

Deskripsi (NVD)

A JSONPath injection vulnerability in Spring AI's AbstractFilterExpressionConverter allows authenticated users to bypass metadata-based access controls through crafted filter expressions. User-controlled input passed to FilterExpressionBuilder is concatenated into JSONPath queries without proper escaping, enabling attackers to inject arbitrary JSONPath logic and access unauthorized documents. This vulnerability affects applications using vector stores that extend AbstractFilterExpressionConverter for multi-tenant isolation, role-based access control, or document filtering based on metadata. The vulnerability occurs when user-supplied values in filter expressions are not escaped before being inserted into JSONPath queries. Special characters like ", ||, and && are passed through unescaped, allowing injection of arbitrary JSONPath logic that can alter the intended query semantics.

Rincian

Terbit di NVD
18 Maret 2026
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
8.6 (High), sumber vmware.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-917: Improper Neutralization of Special Elements used in an Expression Language Statement ('Expression Language Injection')
EPSS (30 hari)
0,53% peluang dieksploitasi; lebih tinggi dari 43,4% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
vmware spring ai Versi 1.0.0 hingga sebelum 1.0.4
vmware spring ai Versi 1.1.0 hingga sebelum 1.1.3

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.